Jennifer Clarke1, Elizabeth Neil2, Robert Terziev2, Philip Gutin3, Igor Barani4, Thomas Kaley2, Andrew B Lassman5, Timothy A Chan6, Josh Yamada6, Lisa DeAngelis2, Ase Ballangrud6, Robert Young7, Katherine S Panageas2, Kathryn Beal6, Antonio Omuro8. 1. Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. 2. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York. 3. Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center, New York, New York. 4. Department of Radiation Oncology, University of California, San Francisco, San Francisco, California. 5. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York; Department of Neurology & Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. 6. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York. 7. Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York. 8. Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York. Electronic address: aomuro@med.miami.edu.
Abstract
PURPOSE: To establish the maximum tolerated dose of a 3-fraction hypofractionated stereotactic reirradiation schedule when delivered with concomitant bevacizumab to treat recurrent high-grade gliomas. METHODS AND MATERIALS: Patients with recurrent high-grade glioma with Karnofsky performance status ≥60, history of standard fractionated initial radiation, tumor volume at recurrence ≤40 cm3, and absence of brainstem or corpus callosum involvement were eligible. A standard 3+3 phase 1 dose escalation trial design was utilized, with dose-limiting toxicities defined as any grade 3 to 5 toxicities possibly, probably, or definitely related to radiation. Bevacizumab was given at a dose of 10 mg/kg every 2 weeks. Hypofractionated stereotactic reirradiation was initiated after 2 bevacizumab doses, delivered in 3 fractions every other day, starting at 9 Gy per fraction. RESULTS: A total of 3 patients were enrolled at the 9 Gy × 3 dose level cohort, 5 in the 10 Gy × 3 cohort, and 7 in the 11 Gy × 3 cohort. One dose-limiting toxicity of grade 3 fatigue and cognitive deterioration possibly related to hypofractionated stereotactic reirradiation was observed in the 11 Gy × 3 cohort, and this dose was declared the maximum tolerated dose in combination with bevacizumab. Although no symptomatic radionecrosis was observed, substantial treatment-related effects and necrosis were observed in resected specimens. The intent-to-treat median overall survival was 13 months. CONCLUSIONS: Reirradiation using a 3-fraction schedule with bevacizumab support is feasible and reasonably well tolerated. Dose-escalation was possible up to 11 Gy × 3, which achieves a near doubling in the delivered biological equivalent dose to normal brain, in comparison with our previous 6 Gy × 5 schedule. Promising overall survival warrants further investigation.
PURPOSE: To establish the maximum tolerated dose of a 3-fraction hypofractionated stereotactic reirradiation schedule when delivered with concomitant bevacizumab to treat recurrent high-grade gliomas. METHODS AND MATERIALS: Patients with recurrent high-grade glioma with Karnofsky performance status ≥60, history of standard fractionated initial radiation, tumor volume at recurrence ≤40 cm3, and absence of brainstem or corpus callosum involvement were eligible. A standard 3+3 phase 1 dose escalation trial design was utilized, with dose-limiting toxicities defined as any grade 3 to 5 toxicities possibly, probably, or definitely related to radiation. Bevacizumab was given at a dose of 10 mg/kg every 2 weeks. Hypofractionated stereotactic reirradiation was initiated after 2 bevacizumab doses, delivered in 3 fractions every other day, starting at 9 Gy per fraction. RESULTS: A total of 3 patients were enrolled at the 9 Gy × 3 dose level cohort, 5 in the 10 Gy × 3 cohort, and 7 in the 11 Gy × 3 cohort. One dose-limiting toxicity of grade 3 fatigue and cognitive deterioration possibly related to hypofractionated stereotactic reirradiation was observed in the 11 Gy × 3 cohort, and this dose was declared the maximum tolerated dose in combination with bevacizumab. Although no symptomatic radionecrosis was observed, substantial treatment-related effects and necrosis were observed in resected specimens. The intent-to-treat median overall survival was 13 months. CONCLUSIONS: Reirradiation using a 3-fraction schedule with bevacizumab support is feasible and reasonably well tolerated. Dose-escalation was possible up to 11 Gy × 3, which achieves a near doubling in the delivered biological equivalent dose to normal brain, in comparison with our previous 6 Gy × 5 schedule. Promising overall survival warrants further investigation.
Authors: Robert B Den; Mitchell Kamrava; Zhi Sheng; Maria Werner-Wasik; Erin Dougherty; Michelle Marinucchi; Yaacov R Lawrence; Sarah Hegarty; Terry Hyslop; David W Andrews; Jon Glass; David P Friedman; Michael R Green; Kevin Camphausen; Adam P Dicker Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: Roger Stupp; Eric T Wong; Andrew A Kanner; David Steinberg; Herbert Engelhard; Volkmar Heidecke; Eilon D Kirson; Sophie Taillibert; Frank Liebermann; Vladimir Dbalý; Zvi Ram; J Lee Villano; Nikolai Rainov; Uri Weinberg; David Schiff; Lara Kunschner; Jeffrey Raizer; Jerome Honnorat; Andrew Sloan; Mark Malkin; Joseph C Landolfi; Franz Payer; Maximilian Mehdorn; Robert J Weil; Susan C Pannullo; Manfred Westphal; Martin Smrcka; Lawrence Chin; Herwig Kostron; Silvia Hofer; Jeffrey Bruce; Rees Cosgrove; Nina Paleologous; Yoram Palti; Philip H Gutin Journal: Eur J Cancer Date: 2012-05-18 Impact factor: 9.162
Authors: Neil K Taunk; Fabio Y Moraes; Freddy E Escorcia; Lucas Castro Mendez; Kathryn Beal; Gustavo N Marta Journal: Expert Rev Anticancer Ther Date: 2016-02-09 Impact factor: 4.512
Authors: O L Chinot; T de La Motte Rouge; N Moore; A Zeaiter; A Das; H Phillips; Z Modrusan; T Cloughesy Journal: Adv Ther Date: 2011-03-14 Impact factor: 3.845
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Wenyin Shi; Joshua D Palmer; Maria Werner-Wasik; David W Andrews; James J Evans; Jon Glass; Lyndon Kim; Voichita Bar-Ad; Kevin Judy; Christopher Farrell; Nicole Simone; Haisong Liu; Adam P Dicker; Yaacov R Lawrence Journal: J Neurooncol Date: 2016-01-29 Impact factor: 4.130
Authors: Corbin A Helis; Shih-Ni Prim; Christina K Cramer; Roy Strowd; Glenn J Lesser; Jaclyn J White; Stephen B Tatter; Adrian W Laxton; Christopher Whitlow; Hui-Wen Lo; Waldemar Debinski; James D Ververs; Paul J Black; Michael D Chan Journal: Neurooncol Pract Date: 2022-05-02
Authors: Tugce Kutuk; Ranjini Tolakanahalli; Nicole C McAllister; Matthew D Hall; Martin C Tom; Muni Rubens; Haley Appel; Alonso N Gutierrez; Yazmin Odia; Alexander Mohler; Manmeet S Ahluwalia; Minesh P Mehta; Rupesh Kotecha Journal: Cancers (Basel) Date: 2022-06-15 Impact factor: 6.575
Authors: Daniel P Kulinich; John P Sheppard; Thien Nguyen; Aditya M Kondajji; Ansley Unterberger; Courtney Duong; Adam Enomoto; Kunal Patel; Isaac Yang Journal: Acta Neurochir (Wien) Date: 2021-04-02 Impact factor: 2.216
Authors: Stephanie E Combs; Maximilian Niyazi; Sebastian Adeberg; Nina Bougatf; David Kaul; Daniel F Fleischmann; Arne Gruen; Emmanouil Fokas; Claus M Rödel; Franziska Eckert; Frank Paulsen; Oliver Oehlke; Anca-Ligia Grosu; Annekatrin Seidlitz; Annika Lattermann; Mechthild Krause; Michael Baumann; Maja Guberina; Martin Stuschke; Volker Budach; Claus Belka; Jürgen Debus; Kerstin A Kessel Journal: Cancer Med Date: 2018-03-23 Impact factor: 4.452